To analyze the impact of nongenetic factors and gene polymorphisms on warfarin dose requirements in elderly Shanghai Han Chinese patients. Genotypes of (rs1799853 and rs1057910), (rs7856096), (rs7412 and rs429358), (rs699664 and rs12714145), (rs4653436, rs1877724, rs1051740 and rs1131873), (rs1800566 and rs10517), (rs1045642), (rs9923231) and (rs2108622) in 214 patients with stable warfarin dose were determined and their demographic characteristics were recorded. Multiple linear regression analysis revealed that rs9923231, rs1057910, rs7412, age, BMI and concomitant amiodarone could explain 37.0% of the individual variations of daily stable warfarin dose. rs9923231, rs1057910, rs7412, age, BMI and concomitant amiodarone play an important role in stable dose variation of warfarin in elderly Shanghai Han Chinese patients, whereas rs1045642 is not a significant genetic factor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs-2019-0139 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
For Atrial Fibrillation, DOACs Outperform Warfarin in Patients with Reduced Kidney Function.
J Am Board Fam Med
January 2025
From the Madigan Army Medical Center Family Medicine Residency, Tacoma, WA (RP, JC, AH).
At standard doses, direct oral anticoagulants (DOACs) were associated with a reduced risk of systemic embolism and intracranial hemorrhage (ICH) when compared with warfarin, with a greater derived benefit at lower creatinine clearance (CrCl-down to 25 mL/min). Lower doses of DOACs were associated with increased overall mortality without a significant decrease in ICH and incident bleeding when compared with standard dose DOACs and warfarin, across all CrCl down to 25 mL/min..
View Article and Find Full Text PDFEffectiveness and Safety of Dose-Specific DOACs in Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Cardiovasc Ther
January 2025
College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan-si, Gyeonggi-do, Republic of Korea.
Dose adjustments of direct-acting oral anticoagulants (DOACs) for atrial fibrillation are based on pivotal clinical trials assessing their effectiveness and safety in controlled settings. However, the appropriateness of these dosing strategies in real-world practice is uncertain. The purpose of this study is to compare the effectiveness and safety of dose-specific DOACs with those of warfarin.
View Article and Find Full Text PDFWarfarin-induced gastrointestinal bleeding with acute liver failure: A case report.
Medicine (Baltimore)
November 2024
Department of Pharmacy, The People's Hospital of Hezhou, Hezhou, China.
Rationale: Warfarin is the most commonly used drug in patients with mechanical valve replacement. Acute liver damage after warfarin is rare but potentially harmful. We present a case of warfarin-induced gastrointestinal bleeding with liver injury, pharmacy monitoring, and its therapy.
View Article and Find Full Text PDFComparison of 4-factor fixed dose versus 4-factor weight-based dose prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis.
Clin Exp Emerg Med
January 2025
Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Objectives: The objective of this systematic review and meta-analysis is to evaluate the efficacy, safety, time to INR reversal, total volume of 4-factor prothrombin complex concentrate (PCC) administered of fixed-dose versus weight-based dosing strategies in patients requiring urgent warfarin reversal, with specific focus on clinical outcomes such as hemostatic efficacy, thromboembolic events, and mortality rates.
Methods: A comprehensive systematic review was conducted using the PubMed, Embase, and Cochrane databases from inception through October 2023. We searched for randomized clinical trials or observational studies that compared efficacy or safety outcomes of fixed-dose vs.
The Impact of Genetic Polymorphism on Complication Development in Heart Failure Patients.
J Clin Med
December 2024
National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
Despite the high progress that has been made in the field of cardiology, the left ventricular assist device (LVAD) can still cause complications (thrombosis/bleeding) in heart failure (HF) patients after implantation. Complications develop due to the incorrect dose of antithrombotic therapy, due to the influence of the non-physiological shear stress of the device, and also due to inherited genetic polymorphisms. Therefore, the aim of our study is to identify the influence of the genetic polymorphisms on complication development in HF patients with implanted LVADs with prescribed antiplatelet therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!